Protagen AG appoints Immuno-Oncology experts to its Scientific Advisory Board
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Protagen AG, a precision medicine specialist at the forefront of immuno-profiling, announced the appointment of Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, Heidelberg, Germany) and Dr. Aurélien Marabelle (Gustave Roussy, Paris, France) to its Scientific Advisory Board.
The new members of Protagen’s Scientific Advisory Board will support the company in the development and implementation of its immuno-profiling technology, with the aim of improving patient selection for novel cancer immunotherapies and offering better management of the risks associated with therapy.
"Protagen feels privileged to bring together the expertise of both Jessica and Aurélien as part of our expanded Scientific Advisory Board. Having dedicated their careers to improving our understanding of cancer and developing new treatment strategies, their extensive knowledge and experience will help to identify how immuno-profiling can advance the prediction of response to immunotherapy and help to avoid immune-related adverse events in cancer patients," said Dr. Georg Lautscham, CEO at Protagen.
Dr. Hassel (pictured left) commented, "The development of a precision medicine approach for the treatment of different cancers will need to address the challenges posed by limited response rates and irAEs. I am delighted to be able to join Protagen’s Scientific Advisory Board to explore these and other pressing issues with other specialists from around the world."
Dr. Marabelle (pictured right) added, "I am very pleased to accept the invitation to join Protagen’s Scientific Advisory Board and look forward to helping the company achieve its vision of unlocking the power of autoantibodies to improve the treatment of cancer patients. It is vital that we understand more about the immunological responses that patients exhibit to cancer, both before and during therapy.
"Protagen established its Scientific Advisory Board in 2015 with the appointment of two experienced and internationally-renowned clinical rheumatology experts: Professor Vibeke Strand, Stanford University, and Professor Matthias Schneider, Duesseldorf University. The expanded Board will help Protagen to develop new ways to implement a precision medicine approach for both the treatment of autoimmune diseases and in immuno-oncology.
The new members of Protagen’s Scientific Advisory Board will support the company in the development and implementation of its immuno-profiling technology, with the aim of improving patient selection for novel cancer immunotherapies and offering better management of the risks associated with therapy.
"Protagen feels privileged to bring together the expertise of both Jessica and Aurélien as part of our expanded Scientific Advisory Board. Having dedicated their careers to improving our understanding of cancer and developing new treatment strategies, their extensive knowledge and experience will help to identify how immuno-profiling can advance the prediction of response to immunotherapy and help to avoid immune-related adverse events in cancer patients," said Dr. Georg Lautscham, CEO at Protagen.
Dr. Hassel (pictured left) commented, "The development of a precision medicine approach for the treatment of different cancers will need to address the challenges posed by limited response rates and irAEs. I am delighted to be able to join Protagen’s Scientific Advisory Board to explore these and other pressing issues with other specialists from around the world."
Dr. Marabelle (pictured right) added, "I am very pleased to accept the invitation to join Protagen’s Scientific Advisory Board and look forward to helping the company achieve its vision of unlocking the power of autoantibodies to improve the treatment of cancer patients. It is vital that we understand more about the immunological responses that patients exhibit to cancer, both before and during therapy.
"Protagen established its Scientific Advisory Board in 2015 with the appointment of two experienced and internationally-renowned clinical rheumatology experts: Professor Vibeke Strand, Stanford University, and Professor Matthias Schneider, Duesseldorf University. The expanded Board will help Protagen to develop new ways to implement a precision medicine approach for both the treatment of autoimmune diseases and in immuno-oncology.
